KINAXO
KINAXO Biotechnologies is a privately-held biotechnology company
based in Munich/Martinsried, Germany. As a spin-off of the Max
Planck Institute of Biochemistry in Martinsried, KINAXO offers
extensive experience in cellular target profiling with several
ongoing pharmaceutical and biotechnology company collaborations, eg
with Boehringer Ingelheim, Johnson & Johnson and Takeda. KINAXO is
financed by European investors BioM, High-Tech Gründerfonds, KfW,
Max Planck Society, and Mountain Partners.
KINAXO’s Cellular Target Profiling™ Service delivers direct insight
into a small molecule’s quantitative binding properties (KD values)
across the proteome of a given cell line or tissue sample. This
interaction profile provides critical guidance within applications
such as lead compound selection for clinical trials, drug
repositioning, target deconvolution, and off-target toxicity
investigations.
Contact
Website: www.kinaxo.com
KINAXO Biotechnologies GmbH Am Klopferspitz 19a 82152 Martinsried,
Germany Phone +49 89 4613363-22
|